CEPI (Coalition for Epidemic Preparedness Innovations, the Oslo-based pandemic-vaccine financing partnership) announced on 22 April 2026 that Moderna has begun the first Phase 3 trial of an mRNA-based H5N1 vaccine candidate, the most advanced position any mRNA H5N1 programme has reached on the public record . Phase 3 is the efficacy and safety stage that precedes regulatory authorisation, conducted at scale and against pre-defined immunogenicity and clinical endpoints.
The usual order of operations runs the other way. Phase 3 typically begins after a pathogen has caused enough disease to enrol participants in a placebo-controlled efficacy trial, which is how COVID-19 vaccines reached authorisation in 2020. For H5N1, that order would mean waiting for a human-to-human transmissible variant to emerge before the vaccine that might prevent its spread had been validated at scale. The CEPI-Moderna trial inverts the sequence by collecting safety and immunogenicity data, and surrogate efficacy markers such as haemagglutination-inhibition titres, before any pandemic strain exists. The unusual design exists precisely because the 100 Days Mission target requires it: authorisation within 100 days of pathogen identification cannot be reverse-engineered from a standing start.
Pre-pandemic Phase 3 immunogenicity data does not automatically translate into an emergency-use authorisation against a future variant; regulators will require bridging studies once a pandemic strain emerges, matching the new haemagglutinin to the trial candidate. Where the trial earns its keep is in the manufacturing and platform validation: an mRNA process already cleared for safety at scale, with cold-chain logistics tested and bulk lipid-nanoparticle supply contracted, can switch antigens within weeks rather than months. The lesson the 2020 COVID vaccine race taught was that the bottleneck rarely sits where the public attention does; the real choke points are reagent supply, bioreactor capacity and regulatory dossier formats.
CEPI also widened its institutional footprint in April. The partnership expanded with the Pasteur Network on 21 April for regional vaccine R&D capacity, and with PAHO on 14 April for regulatory and vaccine-safety capacity in the Americas. The Pasteur expansion adds laboratory capacity in West Africa, Southeast Asia and the Caribbean to the H5N1 surveillance footprint; the PAHO arrangement adds a regional regulatory authority that can run parallel approval timelines to the FDA and EMA. None of this is a vaccine in a vial. All of it is the infrastructure that decides whether a vial, when one is needed, reaches arms in weeks or quarters.
